Australia approves high-dose fish oil drug to protect high-risk heart patients

Australia approves high-dose fish oil drug to protect high-risk heart patients

A poster featuring various fruits, vegetables, and a fish with the text "Eat More Corn, Oats, and Rye Products" promoting nutritious eating to support the army and associates.

Australia approves high-dose fish oil drug to protect high-risk heart patients

Fish oil, a widely used dietary supplement, has long been promoted for its health benefits. Rich in omega-3 fatty acids, it is believed to support heart health, reduce inflammation, and even improve mood. Now, a new high-dose prescription version has become available in Australia for patients at high risk of heart disease.

Interest in fish oil grew in the 1970s when researchers uncovered the heart-protective effects of omega-3 fatty acids. These nutrients, mainly EPA and DHA, help keep cell membranes flexible and fluid, playing a key role in how our bodies function. Over time, studies have linked omega-3s to lower triglyceride levels, reduced joint stiffness in arthritis, and even mild improvements in depression symptoms when combined with antidepressants.

A 2023 review found that taking more than 2 grams of EPA and DHA daily is needed to significantly lower triglycerides. While most people tolerate fish oil well, some experience minor side effects like a fishy aftertaste, nausea, or diarrhoea.

In October 2024, Australia's Therapeutic Goods Administration (TGA) approved Vazkepa, a high-dose omega-3 medication (icosapent ethyl). Since February 2025, it has been subsidised under the Pharmaceutical Benefits Scheme (PBS) for eligible high-risk patients. The monthly cost for patients is around 40 AUD, slightly higher than standard fish oil supplements (20–30 AUD). However, medical guidelines, backed by studies like REDUCE-IT, suggest its benefits may justify the cost for heart health.

Fish oil remains one of the most popular supplements, with proven benefits for heart health and inflammation. The introduction of Vazkepa in Australia offers a targeted, evidence-based option for patients with high cardiovascular risk. For most people, though, standard fish oil supplements continue to provide a safe and affordable way to boost omega-3 intake for heart health.

Neueste Nachrichten